Open AccessCannabidiol modulation of hippocampal glutamate in early psychosis
Author(s) -
Aisling O’Neill,
Luciano Annibale,
Grace Blest-Hopley,
Robin Wilson,
Vincent Giampietro,
Sagnik Bhattacharyya
Publication year - 2021
Publication title -
journal of psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.333
H-Index - 114
eISSN - 1461-7285
pISSN - 0269-8811
DOI - 10.1177/02698811211001107
Subject(s) - cannabidiol , psychosis , glutamate receptor , positive and negative syndrome scale , neurochemical , placebo , antipsychotic , hippocampal formation , psychology , medicine , neuroscience , anesthesia , psychiatry , cannabis , schizophrenia (object oriented programming) , pathology , receptor , alternative medicine
Emerging evidence supports the antipsychotic effect of cannabidiol, a non-intoxicating component of cannabis, in people with psychosis. Preclinical findings suggest that this antipsychotic effect may be related to cannabidiol modulating glutamatergic signalling in the brain.